At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 108 enrolled
Drug / intervention
Apixabandrug
Likely dose
Apixaban 2.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
In Brief
A Phase 3 clinical trial evaluating Apixaban for Myeloma and Venous Thromboembolism. Completed, enrolled 108 participants across 19 sites.
Detailed Summary
To evaluate: * the incidence of venous thromboembolic event (VTE) * the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an oral anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyeloma, Venous Thromboembolism
CountriesFrance
CollaboratorsCelgene
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartJun 2014
Primary CompletionJul 2016
TodayJul 2026
First PostedFeb 19, 2014
Enrollment StartJun 5, 2014
Primary CompletionJul 12, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.4 years ago
Interventions
Apixabandrug
2.5mg x 2 per day during 6 months